Omitting carboplatin from neoadjuvant treatment can improve safety without compromising efficacy in patients with HER2-positive early breast cancer.

A high-fiber diet may improve response rates and event-free survival outcomes in patients with advanced melanoma receiving standard immunotherapy.

Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances in breast cancer.

Adding tafasitamab to treatment with lenalidomide and rituximab improved outcomes in patients with relapsed or refractory follicular lymphoma.

The FDA has approved Monjuvi (tafasitamab-cxix) for use in combination with lenalidomide and rituximab to treat adults with relapsed or refractory follicular lymphoma.

Research presented at ASCO 2025 highlighted potential treatments for patients with newly diagnosed and relapsed or refractory ...

The program significantly shortens the FDA review time for a sponsor's final drug application submission from approximately 10-12 months to 1-2 months.

PTCy plus cyclosporine proved more effective than standard GVHD prophylaxis in patients undergoing matched sibling PBSCT in a phase 3 trial.

Adding lurbinectedin to atezolizumab as first-line maintenance improved PFS and OS in patients with ES-SCLC in the phase 3 ...

An HHS document intended to support the department's change in COVID-19 vaccine policy cites studies that are unpublished or ...

The judge's ruling adds to a growing number of legal decisions halting or scaling back the administration’s actions.

There were no significant differences in progression-free survival or overall survival between the treatment arms. Adding atezolizumab to stereotactic body radiation therapy (SBRT) does not confer ...